Trianni, Inc. and Takeda Pharmaceutical Co. Ltd. have entered into a license agreement under which Takeda will have access to the Trianni Mouse, a monoclonal antibody discovery platform that has been optimized for the isolation of fully human therapeutics.
"We are very pleased to see Takeda adopt the Trianni Mouse," said Dr. Matthias Wabl, Ph.D., chairman and chief executive officer of Trianni. "With its many distinctive features, most notably a full repertoire expressed from chemically synthesized gene segments, we are confident the platform will prove highly productive for Takeda."
"We are excited to add Trianni's transgenic mice to Takeda's repertoire of platform technologies for the generation of therapeutic antibodies," said Tetsuyuki Maruyama, Ph.D., general manager of Pharmaceutical Research Division of Takeda. "Takeda has a growing biologics pipeline and the Trianni Mouse is a natural addition to enhance our ongoing research capabilities in the area."